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LEVOCABASTINE is a new Hi-receptor antagonist
specifically developed for the topical treatment of
seasonal allergic rhinoconjunctivitis. Clinical
experience to date clearly demonstrates that levo-
cabastine eye drops and nasal spray are effective
and well tolerated for the treatment of this
allergic disorder. Analysis of data from a number
of comparative trials reveals that topical levoca-
bastine is at least as effective as sodium
cromoglycate and the oral antihistamine terfena-
dine, even on days with high pollen counts (> 50
3 pollen particles/m ) when symptoms are severe.
Coupled with a rapid onset of action and twice
daily dosing, these findings make topical levoca-
bastine an attractive alternative to other ther-
apeutic approaches as a first-line therapy for the
treatment, of this common condition.
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Introduction
Given the wide array of therapeutic agents
available for the treatment of seasonal allergic
rhinoconjunctivitis, including H-receptor antago-
nists, vasoconstrictors, topical corticosteroids and
sodium cromoglycate, assessment of comparative
efficacy is obviously of considerable importance
for optimal patient management. Comparison of
the true therapeutic efficacy of these different
agents may be somewhat problematic. There are
a number of reasons for this, most notably the
placebo response or spontaneous improvement
in symptoms observed following administration
of any anti-allergic medication and particularly a
topical drug. Response rates greater than 40%
have been reported for placebo eyedrops and
nasal sprays. As the pollen count during the trial
period may not always be sufficient for symp-
toms to develop fully, this placebo response may
mask differences in therapeutic efficacy. A more
realistic assessment of the comparative efficacy of
different therapeutic approaches can be obtained
by comparing efficacy on days with high pollen
counts.
This review will focus on levocabastine, a new
H-receptor antagonist, specifically developed for
the topical treatment of seasonal allergic rhino-
conjunctivitis and a comparison of the ther-
apeutic efficacy of this agent with that of two
other widely used and anti-allergic agents, the
oral Hi-receptor antagonist terfenadine and the
topical mast cell stabilizer sodium cromoglycate.
In particular, emphasis will be placed on the
comparative efficacy of these different ther-
apeutic approaches for the treatment of seasonal
allergic rhinoconjunctivitis on days with high
pollen counts (defined as greater than or equal
to 50 pollen particles/m3).
Levocabastine versus sodium
cromoglycate:
A number of clinical trials have demonstrated
that topical levocabastine is significantly more
effective than sodium cromoglycate for the treat-
ment of seasonal allergic rhinoconjunctivitis,
2-5
However, in only two of these trials were periods
of high pollen counts sufficiently long to permit
separate analysis of therapeutic efficacy as a func-
tion of the pollen count.2’5
Although these were independent trials, the
study protocols were similar. Both were double-
blind, parallel-group trials in patients with sea-
sonal allergic conjunctivitis, with or without con-
current nasal symptoms. Patients were rando-
mized to receive either levocabastine (0.5 mg/
ml), sodium cromoglycate (20 mg/ml) or match-
ing placebo eye drops at a dose of one drop in
each eye four times daily for a period of 4
weeks. Both the patients and the investigators
were required to provide global evaluations of
therapeutic efficacy at the end of the trial. In
addition, the investigators assessed a range of
typical symptoms including ocular irritation,
itching, redness, lacrimation and eyelid oedema,
at the start of the trial, after 2 weeks of treatment
and at the end of the study. Symptom severity
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symptom. The percentage of days when patients
were free from all symptoms was 53% for levoca-
bastine-treated patients compared with 31% for
those treated with sodium cromoglycate (p
0.02) and 34% in the placebo treatment group (p
0.08).
This trend was maintained on days with high
pollen counts (20% of the treatment period)
(Table 1). Only 3% of levocabastine-treated
patients experienced moderate or severe ocular
symptoms on high-pollen days compared with
40% of cromoglycate-treated patients (p 0.01) irritation oedema ocular symptom
FIG. 1. Median area under the curve of daily symptom severity and 36% of those who received placebo (p
derived from the patients" diaries.
2 0.008). For ocular irritation, the percentage of
symptom-free high-pollen days was 57% in the
levocabastine group compared with 28% in the
was graded on a set scale where 0 absent, sodium cromoglycate group (p < 0.02)and 25%
1 mild, 2 moderate, 3 severe. The same in the placebo treatment group (p < 0.03). In
symptoms were assessed by the patients on a addition, lacrimation was absent on 88% of high-
daily basis and recorded on a visual analogue pollen days in the levocabastine group compared
scale (VAS; 0 absent, 100 severe), with 64% (p 0.05) and 58% (p 0.01) of
A total of 60 patients participated in the first days in the other two treatment groups, respec-
study.
2 In all, 18 patients were randomized to tively.
receive levocabastine, 21 to receive sodium cro- The incidence of adverse events was similar in
moglycate and 21 to receive placebo. After 4 all three treatment groups. Ocular irritation fol-
weeks of treatment, the investigator rated global lowing application of the eye drops was the most
therapeutic efficacy to be excellent or good in frequently reported adverse reaction. This was
89% of levocabastine-treated patients compared reported by 13 patients in both the levocabastine
with 67% of those who received sodium cro- and sodium cromoglycate treatment groups and
moglycate (p 0.03) and 48% of those in the eight of those treated with placebo.
placebo group (p 0.007). These findings are suplorted by the results of
Analysis of the patients’ VAS ratings of another published study2 Twenty-eight patients
symptom severity revealed a consistent trend in received levocabastine eye drops, while 32 were
favour of levocabastine (Fig. 1). Statistically sig- treated with sodium cromoglycate and 29
nificant differences in favour of levocabastine received placebo. At the end of the 4-week treat-
were observed for the predominant symptom of ment period, 87% of levocabastine-treated
ocular irritation and the most severe ocular patients rated therapeutic efficacy as excellent or
Table 1, Pecentage of symptom-free days according to patients’ diaries for the entire treatment period and on days
with high pollen counts. Statistically significant intergroup differences are indicated (KruskalI-Wallis test, and if the
KruskalI-Wallis test showed a significant difference amongst the three groups, the Mann-Whitney U-test was
performed).
2
Total period High pollen days
Ocular irritation
Levocabastine 63 57t
p 0.006 p < 0.02
Cromoglycate 36 p < 0.06 28
p 0.44 p < 0.65
Placebo 44 25
Most severe ocular
symptom*
Levocabastine
Cromoglycate
53 44
31
P 0.02
p 0.08
p= 0.85
27
Placebo 34 21
p= 0.01
KW p 0.21"*
*Ocular irritation, redness, lacrimation or swollen eyelids.
**KruskalI-Wallis (KW) one-way analysis of variance.
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ocular administration. Drainage of the levoca-
bastine eye drops through the lacrimal ducts into
the nasal passages is the most likely explanation
for this effect.
After 4 weeks of treatment, lacrimation (p <
0.01), ocular redness (p < 0.05) and the most
severe ocular .symptom (p < 0.05) were sig-
nificantl less severe in levocabastine-treated
patients than in those who received sodium cro-
moglycate. Analysis of the patients’ diaries
revealed that 37% of patients in the levocabastine
group were virtually symptom-free (VAS ratings
< 10) for at least 75% of the treatment period
compared with only 6% of cromoglycate-treated
patients (p < 0.01) and 4% of the placebo
group (p < 0.01).
This trend was maintained on days with high
pollen counts (approximately 54% of the study
period) (Fig. 3). A total of 33% of levocabastine-
treated patients were virtually symptom-free on
FIG. 2. Patients" global evaluations of therapeutic efficacy at the
end of the trial. *p O.O5, **p 0.006 (Mann-Whitney U-test).
5 high-pollen days compared with only 6% of
Reproduced with the kind permission of Munksgaard Int. Pub- those who received sodium cromoglycate (p
lishers Ltd, Copenhagen, Denmark. 0.02) and 4% of the placebo group (p= 0.02).
Both levocabastine and sodium cromoglycate
were well tolerated. As expected, ocular irritation
good compared with 689/o of those treated with following administration of eye drops was the
sodium cromoglycate (p 0.006) and 63% of most frequently reported adverse effect with an
the placebo treatment group (p 0.05) (Fig. 2). incidence of 17.9% for levocabastine, 15.6% for
Symptom severity was generally lower in the sodium cromoglycate and 27.6% in the placebo
levocabastine treatment group. Investigator treatment group.
assessments revealed that levocabastine provided
significantly greater relief of nasal symptoms after Levocabastine versus oral terfenadine 2 weeks of treatment than either sodium cro-
moglycate (p < 0.01) or placebo (p < 0.01). To date, three independent, randomized,
This is of interest, as levocabastine was only double-blind, double-dummy, parallel-group trials
administered ocularly and systemic absorption of have been published which assess the compara-
levocabastine is reported to be minimal following tive efficacy of topical levocabastine and oral ter-
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fenadine for the treatment of seasonal allergic
6-8 rhinoconjunctivitis. Patients were randomized
;.._..._...-...-...-...-...-....-1..’.. .................
to receive either levocabastine eye drops (0.5
mg/ml, one drop in each eye twice daily) and
nasal spray (0.5 mg/ml, two puffs in each nostril
twice daily) plus a twice daily oral placebo or to
receive oral terfenadine (60 mg twice daily) in
combination with placebo eye drops and nasal
spray for a total of 8 weeks.
Both the patients and the investigators per-
formed a global evaluation of therapeutic efficacy
at the end of the study period. In addition, the
investigators rated the severity of ocular symp-
00 >_ 90 _> 80 _> 70 60 50 __> 40 30 >_ 20 __> toms of redness, itching, lacrimation and eyelid
%Dayswith VAS 10 oedema and nasal symptoms of sneezing, rhino-
Sodium rrhoea, itching and congestion on a scale from 0
-’--Levocabastine----.Cromoglycate Placebo to 3 (0 absent, 1 mild, 2 moderate and
(n=27) (n=32) (n=27) 3 severe) at the start of the trial and after 4
FIG. 3. Cumulative distributions of percentages of virtually and 8 weeks of treatment. The patients were
symptom-free (VAS < 10) high-pollen days in the three treat-
ment groups. Reproduced with the kind permission of Munks- required [o assess these symptoms on a daily
gaard Int. Publishers Ltd, Copenhagen, Denmark. basis using a VAS (0 absent, 100 severe).
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The results of these studies show that levoca- period, levocabastine was consistently more
bastine eye drops and nasal spray are at least as effective than oral terfenadine at controlling
effective as oral terfenadine for the treatment of symptoms of seasonal allergic rhinoconjunctivitis.
this allergic condition and statistically significant The incidence of severe lacrimation and ocular
differences in favour of topical levocabastine itching was significantly lower in the levocabas-
were reported even though patients in the terfe- tine group on days with high pollen counts (p <
nadine group also benefited from the use of 0.05), while the percentage of days free from
placebo eye drops and nasal spray. In particular, ocular and nasal itching (p < 0.05) and lacrima-
the available data suggest that topical levocabas- tion (p < 0.01) was significantly higher (Fig. 4).
tine is more effective than oral terfenadine on These findings are supported by those of a
days with high pollen counts.<s A total of 115 smaller trial initiated primarily to assess the toler-
patients with a documented history of grass and/ ability of levocabastine eye drops. In this study,
or birch pollen-induced allergic rhinoconjunctivi- 13 patients were randomized to receive topical
tis participated in the larger of these two trials,
8 levocabastine while 14 were treated with oral ter-
58 of whom were randomized to receive topical fenadine. Use of oral medication and eye drops
levocabastine. Both treatment regimens were was mandatory, however, patients were requested
well-tolerated and the incidence and type of only to use the nasal spray as required. The use
adverse reactions were similar in the two treat- of nasal spray was lower in the levocabastine
ment groups, group (46%) than in the terfenadine group
Global evaluations of therapeutic efficacy (56%), suggesting that topical levocabastine was
revealed a consistent, yet non-significant, trend in more effective at relieving nasal symptoms than
favour of the topical approach. However, after 4 oral terfenadine.
weeks of treatment, investigator assessments In all, 88% of levocabastine-treated patients
revealed that the severity of ocular redness and considered the effect of treatment on ocular
the most severe ocular symptom were sig- symptoms to be excellent or good compared
nificantly lower in the levocabastine group than with 75% of those who received terfenadine,
in the terfenadine group (p < 0.01 and p< 0.05, while 75% of patients in each group were satis-
respectively). Analysis of the patients’ diaries fled with the effect of the study medication on
revealed that VAS ratings were significantly lower nasal symptoms. Investigator assessments
in the levocabastine group for ocular and nasal revealed that symptom severity was consistently
itching (p < 0.05), lacrimation (p 0.001)and lower in the levocabastine treatment group. In
the most severe ocular symptom (p < 0.05). In particular, the severity of ocular itching was sig-
addition, the percentage of symptom-free days nificantly lower (p 0.02) in levocabastine-
was generally higher in the levocabastine group, treated patients than in those who received terfe-
while the percentage of days with severe symp- nadine after 8 weeks of treatment.
toms tended to be lower. Analysis of the patients’ VAS ratings revealed
High pollen counts were recorded during a that levocabastine was significantly more effective
consecutive period of 2 weeks. During this than terfenadine for sneezing (p 0.03), rhino-
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FIG. 4. Percentage of symptom-free high-pollen days in the two treatment groups. *p < 0.05, **p < 0.01.8 Reproduced with the kind
permission of Mosby Year Book Inc., St. Louis, MO, USA.
$24 Mediators of Inflammation Vol 4 (Supplement). 1995Levocabastine on high pollen days
rrhoea (p 0.05) and the most severe nasal
symptom (p 0.02). Furthermore, the percen-
tage of days with severe nasal congestion (p
0.01), rhinorrhoea, sneezing, itching, the most
severe nasal symptom (p < 0.01) and the most
severe of all symptoms (p 0.04) were also sig-
nificantly lower in the levocabastine group.
Analysis of therapeutic efficacy as a function of
the pollen count revealed that this trend was
maintained on high pollen days. Levocabastine
provided significantly greater relief from all nasal
symptoms (p 0.001-0.02) and for the most
severe of all symptoms (p 0.04) than oral ter-
fenadine on days when the pollen count was
high.
Both treatment regimens were well tolerated.
Ocular irritation was the most common adverse
reaction with a similar incidence in the two treat-
ment groups.
Implications for patient management
Clinical experience to date clearly demon-
strates that levocabastine eye drops and nasal
spray are effective and well tolerated for the
treatment of seasonal allergic rhinoconjunctivitis9
with a number of comparative trials revealing
that topical levocabastine is at least as effective as
sodium cromoglycate and oral terfenadine for the
treatment of this common condition, even on
days with high pollen counts. Studies have shown
that treatment efficacy is maintained for up to 4
months,
1 indicating that topical levocabastine is
suitable for long-term therapy throughout the hay
fever season.
Topical levocabastine has a number of distinct
advantages over other agents used to treat sea-
sonal allergic rhinoconjunctivitis. Firstly, levoca-
bastine has an extremely rapid onset of action
providing almost immediate relief from symp-
toms. 11’12 Moreover, unlike sodium cromoglycate,
levocabastine is also effective when administered
after allergen challenge.
In addition, the duration of action of levoca-
bastine is sufficient to permit a convenient, twice-
daily schedule. Patient compliance with such a
regimen is likely to be good. In contrast, other
topical agents for the treatment of seasonal aller-
gic rhinoconjunctivitis must be administered as
frequently as six times daily.
It is obviously important that any anti-allergic
medication is well tolerated during long-term
therapy. Although oral Hi-receptor antagonists
such as terfenadine are generally well tolerated,
topical application of a Hi-receptor antagonist is
preferable as a topical drug is associated with a
minimal risk of systemic adverse effects. Levoca-
bastine eye drops and nasal spray are both well
tolerated. Local irritation following administration
is the most frequently reported adverse reaction
associated with topical levocabastine, however
the incidence is comparable with that observed
following administration of placebo or sodium
cromoglycate.
In conclusion, topical levocabastine is an
attractive alternative to other common thera-
peutic approaches for the treatment of seasonal
allergic rhinoconjunctivitis and the available clin-
ical data clearly support its use as a first-line
therapy for the treatment of this common condi-
tion.
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